Skip to content
AnalystLens

3M CO 8-K Report, Acquisition Completed (Apr 4, 2024)

Reports
Acquisitions & Dispositions·Exhibits & Filings
Filing Date
Filed April 4, 2024
Period End
April 1, 2024
Security
MMM
In the record · 2016–202610-K1110-Q338-K187

MMM filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 187 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Nov ’18Nov ’18
  2. Material agreement8-K · Nov ’20Nov ’20
  3. Impairment8-K · Dec ’22Dec ’22
  4. Material agreement8-K · Aug ’26Aug ’26

01—Abstract

Summary

Summary of the 8-K filed April 4, 2024. Cited figures are marked; the original filing is the authoritative source.

On April 1, 2024, 3M completed the spin-off of its Health Care business as Solventum Corporation (NYSE: SOLV).

3M distributed 80.1%a of Solventum's shares to stockholders at a ratio of one Solventum share for every four 3M shares held as of the March 18, 2024 record date, and retained a 19.9% stake (about 34 million shares). After the Distribution, 3M no longer consolidates Solventum, and Solventum is reported as discontinued operations for all periods. The unaudited pro forma statements show the separation's effect on 3M's scale and balance sheet.

For 2023, pro forma net sales fall from $32.7 billion as reported to $24.8 billionb, and the pro forma loss from continuing operations is $(6.5) billion versus $(7.0) billion as reported. Pro forma total equity at December 31, 2023 is $3.3 billion, down from $4.9 billion. Solventum carries $8.4 billion of debt, and 3M receives about $7.7 billion in cash from the proceeds of Solventum's financings.

3M also estimates a $1.6 billionc gain on its retained stake, valued at $2.4 billion at the April 1, 2024 closing price of $69.10. The filing notes that these figures are preliminary and may change in the 2024 Form 10-K and 10-Qs. For investors, the key points are the large cash inflow, the reduced revenue base, the retained equity stake that will be marked to fair value through continuing operations, and the transition agreements that will keep 3M and Solventum linked through services, manufacturing, distribution, and new commercial arrangements.

02—Key points

Key Highlights

  1. Separation completed April 1, 2024: 80.1% of Solventum shares distributed to 3M stockholders, effective 3:30 a.m. ET, with Solventum trading as SOLV on the NYSE.
  2. Distribution ratio of one Solventum share for every four 3M shares, based on holdings as of the March 18, 2024 record date, with cash paid in lieu of fractional shares.
  3. 3M received approximately $7.7 billion in cash from Solventum's $8.4 billion of debt financings, after fees, discounts, expenses, and Solventum's retention of $0.6 billion of cash.
  4. 3M retained a 19.9% stake (about 34 million shares) valued at $2.4 billion and estimated a $1.6 billion gain, to be measured at fair value on a recurring basis within continuing operations.
  5. Pro forma 2023 net sales decline to $24.8 billion from $32.7 billion as reported, reflecting the removal of Solventum as discontinued operations.
  6. Pro forma total equity at December 31, 2023 falls to $3.3 billion from $4.9 billion, and pro forma goodwill drops to $6.4 billion from $12.9 billion.
  7. Transition services, transition manufacturing and distribution, real estate license, and new commercial agreements link 3M and Solventum after the spin, and their net impacts are reflected in SG&A.

03—Questions

Frequently Asked Questions

  1. What did 3M shareholders receive in the separation?

    Stockholders of record as of the close of business on March 18, 2024 received one share of Solventum common stock for every four shares of 3M common stock held. Cash was paid in lieu of fractional shares. 3M kept a 19.9% ownership stake in Solventum.

  2. How much cash did 3M receive, and what happens to Solventum's debt?

    3M received about $7.7 billion in cash from the proceeds of Solventum's financings, after fees, discounts, and expenses. Solventum took on $8.4 billion of aggregate principal debt at separation and retained $0.6 billion of cash.

  3. How will the retained Solventum stake affect 3M's earnings?

    3M estimated a $1.6 billion gain on its retained 19.9% stake, which was valued at $2.4 billion at the April 1, 2024 closing price of $69.10. 3M will measure this stake at fair value each period, and the resulting changes will flow through continuing operations, which may add earnings volatility.

  4. How do the pro forma results compare with 3M's reported 2023 results?

    Pro forma 2023 net sales are $24.8 billion, versus $32.7 billion as reported, and pro forma net loss from continuing operations attributable to 3M is $(6.5) billion, versus $(7.0) billion as reported. Pro forma figures are illustrative, unaudited, and based on preliminary estimates, so they may differ from future reported results. The filing does not detail the drivers of the 2023 loss.

  5. Are 3M and Solventum still connected after the spin-off?

    Yes. The companies signed transition services, transition contract manufacturing, transition distribution services, and real estate license agreements, plus new commercial agreements covering previously intercompany sales. 3M will reimburse Solventum for certain receivable-related economic benefits in some geographies, and the net impacts of these agreements are reflected in SG&A.

04—Continue

← View all 8-K filings